Literature DB >> 30852962

Outcomes Among Patients With Ischemic Stroke Treated With Intravenous tPA (Tissue-Type Plasminogen Activator) via Telemedicine.

Nicole Anne Wysocki1, Arvind Bambhroliya1, Christy Ankrom1, Farhaan Vahidy1,2, César Astudillo1, Alyssa Trevino1, Rene Malazarte1, T C Cossey1,2, Amanda Jagolino-Cole1,2, Sean Savitz1,2, Tzu-Ching Wu1,2, Anjail Sharrief1,2.   

Abstract

Background and Purpose- Telemedicine is increasingly utilized for intravenous tPA (tissue-type plasminogen activator) delivery. The comparative safety of leaving tPA-treated patients at a presenting (spoke) hospital (drip-and-stay) or transferring patients to a central treating (hub) hospital (drip-and-ship) is not established. We sought to compare outcomes between drip-and-ship and drip-and-stay patients treated with tPA via telemedicine. We hypothesized that there would be no differences in short-term outcomes of in-hospital mortality, length of stay, or discharge disposition or in 90-day outcomes between groups. Methods- We retrospectively identified patients treated with tPA at 17 spoke hospitals between September 2015 and December 2016. Demographic, clinical, and outcome data were obtained from a prospective telemedicine registry. We used negative binomial, multinomial, and logistic regression analyses to evaluate length of stay, discharge disposition, and inpatient mortality, respectively. We compared the proportion of patients with 90-day modified Rankin Scale score <2 by group. Results- Among 430 tPA-treated patients, 232 (53.9%) were transferred to the hub after treatment. The median arrival National Institutes of Health Stroke Scale score was higher for drip-and-ship (10; interquartile range, 5-18) compared with drip-and-stay patients (6; interquartile range, 4-10; P<0.001). Unadjusted length of stay was longer in drip-and-stay patients (incidence rate ratio, 0.82; 95% CI, 0.71-0.95). There were no significant differences in adjusted length of stay, hospital mortality, or discharge disposition. Among the 64% of patients with complete 90-day modified Rankin Scale score, the proportion with good outcomes (modified Rankin Scale score <2) did not differ between groups. Conclusions- We found no differences in measured outcomes between drip-and-ship and drip-and-stay patients treated in our network, although our study may be underpowered to detect small differences.

Entities:  

Keywords:  hospitals; humans; inpatients; registries; telemedicine

Mesh:

Substances:

Year:  2019        PMID: 30852962      PMCID: PMC7384440          DOI: 10.1161/STROKEAHA.118.024703

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  18 in total

1.  Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe.

Authors:  Muhammad A Pervez; Gisele Silva; Shihab Masrur; Rebecca A Betensky; Karen L Furie; Renzo Hidalgo; Fabricio Lima; Eric S Rosenthal; Natalia Rost; Anand Viswanathan; Lee H Schwamm
Journal:  Stroke       Date:  2009-11-12       Impact factor: 7.914

2.  Telestroke-guided intravenous tissue-type plasminogen activator treatment achieves a similar clinical outcome as thrombolysis at a comprehensive stroke center.

Authors:  Syed F Zaidi; Mouhammad A Jumma; Xabier N Urra; Maxim Hammer; Lori Massaro; Vivek Reddy; Tudor Jovin; Ridwan Lin; Lawrence R Wechsler
Journal:  Stroke       Date:  2011-09-01       Impact factor: 7.914

3.  Outcomes of Spoke-Retained Telestroke Patients Versus Hub-Treated Patients After Intravenous Thrombolysis: Telestroke Patient Outcomes After Thrombolysis.

Authors:  Danielle L Heffner; Parthasarathy D Thirumala; Pooja Pokharna; Yue-Fang Chang; Lawrence Wechsler
Journal:  Stroke       Date:  2015-09-22       Impact factor: 7.914

4.  Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals.

Authors:  S D Reed; D K Blough; K Meyer; J G Jarvik
Journal:  Neurology       Date:  2001-07-24       Impact factor: 9.910

Review 5.  [The application of telemedicine for stroke in the Balearic Islands: the Balearic Telestroke project].

Authors:  M Carmen Jiménez; Silvia Tur; Inés Legarda; Bárbara Vives; Arantza Gorospe; M José Torres; Paz Merino; Carlos Campillo
Journal:  Rev Neurol       Date:  2012-01-01       Impact factor: 0.870

Review 6.  Stroke care using a hub and spoke model with telemedicine.

Authors:  Penny Huddleston; Mary Beth Zimmermann
Journal:  Crit Care Nurs Clin North Am       Date:  2014-11-08       Impact factor: 1.326

7.  Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals.

Authors:  Lee H Schwamm; Syed F Ali; Mathew J Reeves; Eric E Smith; Jeffrey L Saver; Steven Messe; Deepak L Bhatt; Maria V Grau-Sepulveda; Eric D Peterson; Gregg C Fonarow
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2013-09-01

8.  Impact of telemedicine implementation in thrombolytic use for acute ischemic stroke: the University of Pittsburgh Medical Center telestroke network experience.

Authors:  Edilberto Amorim; Min-Mei Shih; Steven A Koehler; Lori L Massaro; Syed F Zaidi; Mouhammad A Jumaa; Vivek K Reddy; Maxim D Hammer; Tudor G Jovin; Lawrence R Wechsler
Journal:  J Stroke Cerebrovasc Dis       Date:  2013-03-13       Impact factor: 2.136

9.  Long-term outcome after thrombolysis in telemedical stroke care.

Authors:  S Schwab; B Vatankhah; C Kukla; M Hauchwitz; U Bogdahn; A Fürst; H J Audebert; M Horn
Journal:  Neurology       Date:  2007-08-28       Impact factor: 9.910

10.  The effect of a stroke unit: reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost. A community-based study.

Authors:  H S Jørgensen; H Nakayama; H O Raaschou; K Larsen; P Hübbe; T S Olsen
Journal:  Stroke       Date:  1995-07       Impact factor: 7.914

View more
  1 in total

Review 1.  Stroke and digital technology: a wake-up call from COVID-19 pandemic.

Authors:  Francesco Iodice; Michele Romoli; Bruno Giometto; Marinella Clerico; Gioacchino Tedeschi; Simona Bonavita; Letizia Leocani; Luigi Lavorgna
Journal:  Neurol Sci       Date:  2021-01-12       Impact factor: 3.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.